Interestingly, the peroxisome proliferator-activated receptor gamma agonist pioglitazone also restores FABP4 levels and augments RV function in the Sugen-hypoxia model of PAH (22), which suggests combatting FABP4 downregulation may have therapeutic relevance for RV failure. This evidence concerns the gene FABP4 and pulmonary arterial hypertension.